I agree with you @Slogger that change is required. For me and IMO the CEO is not the issue I would start with the chairman who I feel is feathering his own nest, not thinking of what's best for ACR and then work down to other directors. Brooke made his $$, Oldham too focussed on AdAlta.
Chairman delivered Axiron - massive tick while it lasted but mitigated in part by the patents he created being smashed in court, delivered Hexima - horrible and now snoozy generic strategy. His use-by date is long gone for me.
ACR Price at posting:
7.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)